Rosuvastatin

Introduction Overview

Generic Name

rosuvastatin

Brand Name

Crestor, Ezallor Sprinkle

Dosage Form

oral tablet, oral capsule

Drug Class

Statins (HMG-CoA reductase inhibitors)

Pharmacokinetics

Absorption:
Rosuvastatin is orally administered and exhibits moderate bioavailability, estimated at roughly 20%. Peak plasma concentrations are typically attained within 3 to 5 hours following oral dosing. Although food can delay the time to reach peak levels, it does not significantly affect the extent of absorption, allowing for administration with or without meals. The drug is formulated as tablets and as a sprinkle capsule to accommodate patients with swallowing difficulties, enhancing its clinical applicability. Unlike some statins extensively metabolized in the gastrointestinal tract, rosuvastatin has high solubility and moderate permeability, facilitating its consistent absorption profile.

Distribution:
Rosuvastatin exhibits moderate plasma protein binding of approximately 88%, primarily binding to albumin. It is extensively distributed in the liver, the primary target organ, by active uptake via hepatic transporters including OATP1B1 and OATP1B3. The volume of distribution reported ranges between 134 liters, suggesting extensive tissue uptake. The selective hepatic uptake reduces peripheral tissue exposure, which contributes to its safety profile by minimizing systemic side effects. There is limited penetration into the central nervous system due to low blood-brain barrier permeability, reducing risks of neurological adverse effects.

Metabolism:
Rosuvastatin undergoes minimal metabolism compared to other statins, with approximately 10% of the systemic drug metabolized. The primary metabolic pathways include CYP2C9-mediated hydroxylation and, to a lesser extent, CYP2C19. The major metabolites are pharmacologically inactive. This limited metabolism results in fewer drug-drug interactions mediated through cytochrome P450 enzymes and contributes to the drug's relatively predictable pharmacokinetics. This metabolic profile also reduces the likelihood of interactions common with statins metabolized by CYP3A4.

Elimination:
Rosuvastatin has an elimination half-life ranging from 19 to 27 hours, facilitating once-daily dosing. Excretion occurs predominantly via the feces, accounting for approximately 90% of the administered dose, primarily as unchanged drug. Renal clearance accounts for around 28% of elimination, with minimal renal metabolism. The reliance on biliary and fecal routes for clearance suggests caution in patients with severe hepatic impairment due to potential drug accumulation. Dose adjustment is recommended in patients with moderate to severe renal dysfunction as clearance may be reduced. Overall, the elimination mechanisms support dosing flexibility and safety in various patient populations.

Dosage Forms

Available Dosage Forms:
- Oral tablets (Crestor): 5 mg, 10 mg, 20 mg, and 40 mg
- Oral capsules (Ezallor Sprinkle): 5 mg, 10 mg, 20 mg, and 40 mg granules inside gelatin capsule shell, designed to be opened and sprinkled onto soft food for patients with swallowing difficulties

Dosages for Adults and Adolescents:
- Adults: Initial dose typically 10 mg once daily; dose range 5 to 40 mg once daily. The 40 mg dose is reserved for patients not achieving LDL cholesterol goals with 20 mg.
- Adults with homozygous familial hypercholesterolemia: Starting dose 20 mg once daily.
- Pediatric patients (heterozygous familial hypercholesterolemia, ages 8 to <10 years): 5 to 10 mg once daily.
- Pediatric patients (heterozygous familial hypercholesterolemia, ages 10 to 17 years): 5 to 20 mg once daily.
- Pediatric patients (homozygous familial hypercholesterolemia, ages 7 to 17 years): 20 mg once daily.

Specific Patient Populations:
- Elderly: No initial dose adjustment recommended, but caution advised due to increased risk of muscle-related adverse effects.
- Renal impairment: Dose reduction recommended for moderate to severe impairment; initiation at lower doses and close monitoring is advised.
- Hepatic impairment: Rosuvastatin is contraindicated in active liver disease or unexplained persistent elevations of hepatic transaminases.
- Patients of Asian descent: Typically require lower initial doses due to higher plasma concentrations observed.

Dosing Instructions and Clinical Guidelines:
- Tablets may be taken any time of day, with or without food.
- Capsules must be swallowed whole or opened and sprinkled on soft food; granules should be consumed within 60 minutes without chewing.
- When administered via nasogastric tube (≥16 French), the capsule granules can be suspended in water and administered immediately.
- Dose adjustments should be guided by lipid response and tolerability; liver function tests and creatine kinase levels should be monitored periodically.

Mechanism Of Action

Rosuvastatin functions primarily as a potent competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in hepatocytes. By binding to and inhibiting this enzyme, rosuvastatin effectively reduces endogenous cholesterol synthesis within the liver cells. This results in a compensatory upregulation of LDL receptors on hepatocyte surfaces, enhancing the clearance of circulating low-density lipoprotein cholesterol (LDL-C) from the bloodstream.

Furthermore, rosuvastatin increases hepatic uptake of LDL particles and promotes degradation of LDL cholesterol, thereby lowering plasma LDL-C levels substantially. It also favorably modulates lipid profiles by moderately raising high-density lipoprotein cholesterol (HDL-C) and reducing triglyceride concentrations through improved lipid metabolism. These effects collectively contribute to the reduction of atherosclerotic plaque formation in vascular walls.

On a cellular level, rosuvastatin also exerts pleiotropic effects beyond lipid lowering, including improvement of endothelial function, stabilization of atherosclerotic plaques, antioxidative properties, and anti-inflammatory actions. The drug's ability to improve nitric oxide bioavailability enhances vascular relaxation and reduces oxidative stress, which contributes to cardiovascular risk reduction.

Compared with other statins, rosuvastatin has a higher affinity for HMG-CoA reductase, resulting in greater potency and efficacy at lower doses. Clinical trials have demonstrated its superiority in LDL-C reduction and cardiovascular event prevention compared to several other statins. This mechanism and pharmacological profile underpin its prominent role in dyslipidemia management and cardiovascular risk mitigation.

Pharmacological Actions

Potent inhibition of HMG-CoA reductase, reducing hepatic cholesterol synthesis.
Upregulation of LDL receptors in the liver, increasing LDL cholesterol clearance from blood.
Reduction of plasma LDL cholesterol and triglycerides, with moderate elevation of HDL cholesterol.
Improvement of endothelial function and nitric oxide bioavailability.
Anti-inflammatory and antioxidative effects contributing to plaque stabilization.
Reduction of progression of atherosclerosis and cardiovascular risk.
Minimal metabolism via CYP2C9, lowering potential for cytochrome P450-mediated interactions.
Favorable pharmacokinetic profile enabling once-daily dosing.
Selective hepatic uptake via organic anion transporting polypeptides (OATPs).
Safety profile supported by low penetration into central nervous system.
Pleiotropic vascular protective effects beyond lipid lowering.
Dose-dependent lipid lowering efficacy.
Reduced incidence of drug interactions compared to CYP3A4-metabolized statins.
Approved for use in pediatric patients with familial hypercholesterolemia.
Potential beneficial effects on high-sensitivity C-reactive protein (hsCRP) levels.

Therapeutic Or Clinical Uses

Treatment of primary hypercholesterolemia and mixed dyslipidemia to reduce LDL cholesterol levels.
Management of heterozygous familial hypercholesterolemia in children aged 8 years and older and adults.
Treatment of homozygous familial hypercholesterolemia in patients 7 years and older.
Reduction of cardiovascular risk by decreasing incidence of heart attacks and strokes in adults with additional risk factors.
Adjunctive therapy to diet for lowering elevated total cholesterol, LDL cholesterol, and triglycerides.
Increasing HDL cholesterol levels in patients with dyslipidemia.
Prevention of cardiovascular events in patients without established cardiovascular disease but with risk factors.
Use in adults who cannot control cholesterol with diet and exercise alone.
Alternative statin choice for patients requiring potent LDL-C reduction with minimal drug interactions.
Treatment option for patients intolerant to other statins due to better safety profiles concerning muscle toxicity.
Adjunctive treatment in patients with mixed hyperlipidemia, including elevated triglycerides.
Selected use in special populations such as Asian descent with dose adjustments.
Use for patients requiring therapeutic flexibility to administer medication as sprinkle capsules.
Support in managing lipid profiles in patients with metabolic syndrome.
Improvement of surrogate markers of cardiovascular risk beyond lipid control.

Side Or Adverse Effects

Myopathy including muscle pain, tenderness, or weakness, which may progress to rhabdomyolysis in rare cases.
Elevated liver enzymes indicating potential hepatotoxicity.
Headache and common neurologic complaints such as dizziness.
Gastrointestinal symptoms including abdominal pain, nausea, and dyspepsia.
Fatigue and generalized weakness.
Rare reports of memory loss and cognitive impairment (e.g., confusion).
Increased risk of muscle-related adverse events in elderly patients and those with renal dysfunction.
Potential for elevated serum creatine kinase levels.
Hypersensitivity reactions including rash and pruritus.
Rare instances of severe allergic reactions including angioedema.
Possible elevation of blood glucose and new-onset diabetes mellitus in predisposed individuals.
Muscle symptoms may be more frequent when used concomitantly with interacting drugs.
Post-marketing reports of tendon rupture in patients using statins including rosuvastatin.
Potential for increased risk of hemorrhagic stroke in some populations.
Drug-induced liver injury presenting as fatigue, jaundice, or dark urine.

Precautions

Use with caution in patients with a history of liver disease or elevated hepatic transaminases.
Monitor for unexplained muscle pain or weakness, especially with concomitant medications increasing myopathy risk.
Adjust dose or avoid use in patients with moderate to severe renal impairment.
Caution advised in elderly patients due to increased risk of adverse effects.
Assess baseline and periodic liver function tests during therapy.
Careful consideration when prescribing to patients consuming substantial quantities of alcohol.
Consider dose adjustment in patients of Asian descent due to higher plasma exposure.
Avoid abrupt discontinuation without physician guidance to prevent loss of lipid control.
Evaluate thyroid function as untreated hypothyroidism can increase risk of myopathy.
Avoid concomitant use with potent CYP2C9 inhibitors unless benefit outweighs risk.
Counsel patients regarding the risk and symptoms of myopathy and liver dysfunction.
Not recommended during pregnancy or lactation due to potential fetal and infant harm.
Ensure adherence to cholesterol-lowering diet during treatment for optimal efficacy.
Use cautiously with other lipid-modifying therapies to reduce risk of side effects.
Dose modifications may be necessary based on lipid response and tolerability.

Warnings

Contraindicated in active liver disease or unexplained persistent elevations in liver enzymes.
Risk of serious muscle toxicity including rhabdomyolysis, potentially leading to acute renal failure.
Discontinue immediately if signs of myopathy or hepatotoxicity occur.
Elevated risk of muscle-related adverse events when used with certain medications such as cyclosporine, gemfibrozil, or antivirals.
Not recommended for use during pregnancy due to fetal risk; effective contraception is required.
Avoid use during breastfeeding as rosuvastatin can pass into breast milk and harm the infant.
Use with caution in patients with predisposing factors for muscle disorders including renal impairment and advanced age.
Watch for symptoms suggestive of liver injury such as jaundice, fatigue, and abdominal pain.
Counsel patients to report any unexplained muscle pain, tenderness, or weakness promptly.
Avoid coadministration with antacids containing aluminum and magnesium within 2 hours of dose to prevent reduced absorption.
Discontinuation of therapy should be guided by healthcare provider to avoid rebound lipid elevations.
Patients should inform healthcare providers of all concurrent medications to evaluate interaction risks.
Not for use in children younger than age 7-8 depending on familial hypercholesterolemia type.
Periodic monitoring of lipid panel and liver enzymes is essential during treatment.
Risk-benefit assessment required for patients with multiple risk factors for adverse effects.

Contraindication

Known hypersensitivity to rosuvastatin calcium or any component of the formulation.
Active liver disease or unexplained persistent elevations in hepatic transaminases.
Pregnancy and lactation due to potential teratogenic risk and harm to nursing infants.
Severe renal impairment without appropriate dose adjustment and close monitoring.
Concurrent use with certain drugs contraindicated due to interaction risks causing serious toxicity (e.g., cyclosporine without dose adjustment).
Pediatric patients younger than 7 years for homozygous familial hypercholesterolemia due to lack of safety data.
Pediatric patients younger than 8 years for heterozygous familial hypercholesterolemia as rosuvastatin tablets are not approved.
Patients with active muscle disease or history of statin-induced myopathy without supervision.
Use in clinical conditions associated with uncontrolled hypothyroidism until thyroid function is normalized.
Patients requiring concomitant use of strong inhibitors of rosuvastatin metabolism causing excessive plasma concentrations.
Patients with known sensitivity to any rosuvastatin capsule or tablet inactive ingredients.
Individuals with significant alcohol abuse due to increased risk of hepatotoxicity.
Patients with unexplained persistent elevations of creatine kinase.
Use in individuals with hemophilia or other bleeding disorders without clinical justification.
Concurrent use with certain investigational agents with adverse pharmacodynamic interactions.

Drug Interactions

Cyclosporine markedly increases rosuvastatin plasma concentration; coadministration requires dose adjustment.
Gemfibrozil and other fibrates increase risk of myopathy and rhabdomyolysis when combined with rosuvastatin.
Darolutamide can increase rosuvastatin levels; concomitant use should be carefully managed.
Regorafenib can elevate rosuvastatin plasma concentration, increasing adverse effect risks.
Certain antiretroviral medications (e.g., lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir) increase rosuvastatin exposure.
Hepatitis C antivirals including sofosbuvir/velpatasvir/voxilaprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, and others raise rosuvastatin levels, elevating risk of toxicity.
Azole antifungals (itraconazole, ketoconazole, fluconazole) may increase rosuvastatin blood levels.
Coumarin anticoagulants like warfarin may have altered anticoagulant effects when used with rosuvastatin.
Niacin and nicotinic acid coadministration can increase risk of muscle toxicity.
Colchicine, when combined with rosuvastatin, raises potential for serious myopathy.
Drugs that inhibit OATP1B1 transporter can increase rosuvastatin plasma levels.
Antacids containing aluminum and magnesium can reduce rosuvastatin absorption; separation of administration by at least 2 hours is recommended.
Avoid combining with other lipid-lowering agents without clinical monitoring to mitigate adverse effects.
Potential additive hepatic toxicity with other hepatotoxic drugs.
Immunosuppressants and certain cancer therapies may have clinically significant interactions requiring dose modification.

Preparations Of The Drug

Crestor tablets: immediate-release oral tablets available in 5 mg, 10 mg, 20 mg, and 40 mg strengths marketed by AstraZeneca Pharmaceuticals LP.
Ezallor Sprinkle capsules: immediate-release oral gelatin capsules containing granules with strengths of 5 mg, 10 mg, 20 mg, and 40 mg manufactured by Sun Pharmaceutical Industries Ltd.
Generic rosuvastatin tablets: multiple manufacturers offering various formulations and dosages with similar inactive ingredients variations.
Capsules feature a colored gelatin shell with specific FD&C and D&C colorants depending on strength to facilitate identification.
Inactive ingredients in Crestor tablets include microcrystalline cellulose, lactose monohydrate, tribasic calcium phosphate, crospovidone, magnesium stearate, hypromellose, triacetin, titanium dioxide, and iron oxides.
Inactive ingredients in Ezallor Sprinkle capsules include microcrystalline cellulose, crospovidone, mannitol, magnesium oxide, ferric oxide, sodium citrate, hypromellose, polyethylene glycol 4000, and silicon dioxide.
Capsule ink imprinting contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide, purified water, and potassium hydroxide.
Formulations are designed to optimize bioavailability, patient compliance, and ease of administration including for the elderly and pediatric patients.
Packaging typically includes patient instructions for administration with or without food and specific techniques for capsules to be sprinkled on soft food or administered via nasogastric tube.
Storage recommendations emphasize maintaining room temperature (20-25°C), dry conditions, and protection from children.
Product labeling includes detailed information on dosing, contraindications, precautions, and interaction warnings to ensure safe use.
Manufacturing quality adheres to regulatory standards to ensure consistency and efficacy of the rosuvastatin preparations across brands.
Special dispensing instructions apply for the sprinkle capsule formulation to preserve stability and ensure proper dosing.
Available through prescription only due to need for medical supervision and monitoring during therapy.
Distributed in the US with licensing agreements between AstraZeneca for Crestor tablets and Sun Pharma for Ezallor Sprinkle capsules.